

Global Liver Institute

NASH PORTFOLIO



Global Liver Institute's (GLI) NASH portfolio leads the fight against nonalcoholic steatohepatitis (NASH), the advanced form of nonalcoholic fatty liver disease (NAFLD). GLI is dedicated to ensuring that the public and every patient have access to the full spectrum of preventatives, diagnostics, and treatments. The NASH Council, comprising over 90 member organizations, including patient advocacy groups, medical societies, and government agencies, champions fatty liver disease as a prominent public health concern. The Council advocates for patient priorities, amplifying the voice of the liver disease community in key regulatory and legislative realms.

GLI's NASH Vision

- Universal public awareness of fatty liver disease and its advanced forms worldwide
- Guaranteed precise and prompt detection and management of fatty liver disease
- Suitable options of specialized therapies for fatty liver disease depending on patient stage and goals
- Policy and reimbursement structures that ensure fair access to crucial NASH treatments
- NASH at the forefront of public health initiatives, specific policies, and legislative and programmatic measures across the U.S., EU, and international forums



[Learn more](#)

An estimated
1 in 4 people
worldwide have
fatty liver disease.

NIDDK, 2021

Achievements

- GLI and NASH patients addressed critical gaps in ICER's evaluation of NASH treatments on April 28, 2023, highlighting the need for comprehensive assessment.
- GLI spearheaded contributions from the liver advocacy community during the FDA Gastrointestinal Drugs Advisory Committee (GIDAC) meeting on May 19, 2023, advocating for the application of obeticholic acid (OCA) as a viable NASH treatment.
- The U.S. NASH Action Plan 2022 Scorecard showcased significant strides made by various stakeholders, as outlined in the comprehensive U.S. NASH Action Plan.
- The collaborative effort between GLI and NutriStyle Inc. resulted in the creation of GLI APPetite™, a tailored nutrition app benefiting individuals with liver disease, diabetes, and other chronic conditions.
- Patients shared their experiences at the inaugural NASH Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting for the U.S. FDA on November 4, 2021, to emphasize the urgency for NASH therapies.

2024 Goals

- Lead focused discussions and robust advocacy initiatives to secure formal regulatory approval for NASH treatments, so patients have access to an array of effective treatment choices
- Develop clinician education resources in collaboration with partners, with a focus on pediatric and primary care specialists, to ensure accurate and timely diagnosis as part of Global Fatty Liver Day
- Collaborate with health organizations to establish routine screening for fatty liver disease as a coexisting condition, alongside diabetes and obesity, to ensure timely assessments for at-risk individuals
- Develop and distribute support resources for veterans with or at risk of fatty liver disease in partnership with the Veterans' Health Administration



Beyond the Biopsy

GLI's Beyond the Biopsy program boosts the acceptance and utilization of non-invasive diagnostics as an alternative to liver biopsy by amplifying their merits, addressing barriers to adoption, and promoting integration into best practices and guidelines.



Global Fatty Liver Day

Global Fatty Liver Day, *formerly known as International NASH Day*, is an annual public education campaign launched in June 2018 to enhance awareness and emphasize the pressing nature of fatty liver disease, which is projected to reach a global prevalence of 55% by 2040 (Clinical and Molecular Hepatology, 2023). It provides support to patients in navigating through the confusing aspects of diagnosis, screening, treatment, awareness, naming, and clinical trials. Global Fatty Liver Day highlights the disease's severe, advancing impact, empowering patients and caregivers to take action to maximize their liver health.

2023 Campaign at a Glance

10M
SOCIAL MEDIA IMPRESSIONS

100+
PARTNERS

50
COUNTRIES

31
ORGANIZATIONAL ENDORSEMENTS



[Learn more](#)



Cameroon



Croatia



India

Council Members

- Allergan
- American Association for the Study of Liver Diseases
- American Association of Clinical Endocrinologists
- American Association of Nurse Practitioners
- American Cancer Society
- American College of Physicians
- American College of Physicians Assistants
- American College of Sports Medicine
- American Gastroenterological Association
- American Heart Association
- American Nursing Association
- American Society for Gastrointestinal Endoscopy
- Amsety
- Apollo EndoSurgery
- Arizona Liver Health
- Association of American Medical Colleges
- BlackDoctor, Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Boston Scientific
- Bristol-Myers Squibb
- Canadian Liver Foundation
- Cancer and Chronic Disease Prevention: DC Department of Health
- Cardiometabolic Health Congress
- Celgene Corporation
- Center for Medical Technology Policy
- Clinical Care Options
- Community Liver Alliance
- Council for a Strong America
- diaTribe
- Duke University School of Medicine
- Endocrine Society
- European Liver Patients Association
- Fatty Liver Foundation
- Fondazione Italiana Fegato ONLUS
- Gartman PR
- Genfit Corporation
- George Washington University - Milken Institute School of Public Health
- Gilead Sciences, Inc.
- Gut and Liver Foundation
- Guy's and St Thomas' Hospital, NHS Foundation Trust, University College London, Institute for Liver and Digestive Health, Royal Free Hospital
- Hepatitis Hilfe Österreich - Austrian Patients Association
- Institute of Liver Diseases at King's College London
- Integritas Communications
- Intercept Pharmaceuticals
- Inventiva
- Joslin Diabetes Center
- Karolinska Institute/University Hospital
- Liver Patients International
- Liver Wellness Foundation
- Madrigal Pharmaceuticals
- Massachusetts General Hospital/Harvard Medical School
- McGuire VA Medical Center
- Medical University of South Carolina
- Merck
- Metabolys Inc. (MHP Salud)
- MHP Salud (formerly Migrant Health)
- Mid South Liver Alliance
- NASH kNOWledge
- NASHNet
- National Alliance for Hispanic Health (NAHH)
- National Center for Weight and Wellness/Obesity Society
- National Hispanic Medical Association
- National Lipid Association
- National Medical Association
- Nestle Health Science
- North American Society For Pediatric Gastroenterology, Hepatology & Nutrition
- Northwestern University
- Novo Nordisk, Inc.
- Obesity Action Campaign
- Perspectum Diagnostics LTD
- Pfizer Inc.
- Physicians Committee for Responsible Medicine
- Preventive Cardiovascular Nurses Association
- Regeneron Pharmaceuticals
- Rush University
- Rutgers University
- Save Liver Association for Patients (SLAP)
- STOP Obesity Alliance
- Tampa General Medical Group/ USF Tampa
- Target-NASH PharmaSolutions
- Tawazun Health
- The Liver Forum
- U.S. Food & Drug Administration (FDA)
- UCSF Medical Center
- University of Michigan, NAFLD Clinic
- Virginia Commonwealth University School of Medicine



Learn more